Skip to content
Review Open access

67 Limited-stage small cell lung cancer – how to address the high risk of intracranial metastases?

Aug 2026 · Neuro-Oncology · Vol 28 · 0 citations

TL;DR

Avoiding prophylactic cranial irradiation (PCI) for patients with limited-stage SCLC may spare patients long-term neurocognitive and quality-of-life sequelae, and suggest selected patients may achieve favourable outcomes with initial surveillance.

Abstract

Small cell lung cancer (SCLC) accounts for approximately 15% of lung cancers and is characterised by rapid proliferation, early dissemination and poor prognosis. It has a strong predilection for brain metastases, with around 10% of patients presenting with intracranial disease. Current standard of care recommends prophylactic cranial irradiation (PCI) for patients with limited-stage (LS) SCLC who respond to initial therapy. However, scrutiny of practice in the modern era does not necessarily reflect this. A retrospective review was conducted of all patients diagnosed with LS SCLC between January 2019 and July 2024 at Imperial College Healthcare NHS Trust. Seven patients (20%) completed PCI. Eighteen patients did not undergo PCI, and nine experienced progression, died, or declined treatment prior to consideration. Among patients receiving PCI (mean age 65 years), three had died and four were alive at analysis. All deaths in the PCI group were associated with intracranial progression. Of surviving PCI patients, 75% had no evidence of intracranial progression. All intracranial progression events occurred within 12 months of PCI. In the non-PCI group (mean age 71 years), 44% were alive without intracranial progression at follow-up, while 56% had died; of those who died, 40% experienced intracranial progression. Many patients managed without PCI remain alive and free from intracranial progression, demonstrating favourable real-world outcomes. With recent trials failing to replicate survival benefits previously reported and in the modern era of MRI surveillance, avoiding PCI may spare patients long-term neurocognitive and quality-of-life sequelae. Advances in radiotherapy, including stereotactic radiosurgery and systemic therapies with immunotherapy, further challenge PCI’s traditional role. These findings reflect evolving practice and suggest selected patients may achieve favourable outcomes with initial surveillance.

Read PDF

Similar papers

Open access Aug 2026

94 Outcome of patients with metastatic lung cancer presenting with synchronous brain metastases – A single centre; 5 year retrospective analysis

There was so significant difference in number of patients receiving local brain treatment based on PDL1 and molecular genetic status that Prospective randomised clinical trials are needed to test the utility of upfront local intracranial treatments in this cohort.

Harriet Hebbes, Sara Walters, Patrick Forster et al. · 0 citations
Open access Oct 2026

Clinical and Demographic Characteristics of Patients with Pulmonary Large-Cell Neuroendocrine Carcinoma: A Single-Center Experience

Background and Objectives: Pulmonary large-cell neuroendocrine carcinoma (pLCNEC) is a rare malignancy, accounting for approximately 2–3.5% of surgically resected primary lung cancers. Given its rarity, pLCNEC has been less extensively studied than other, more common lung cancer subtypes. In this study, we evaluated an...

Yeşim Özufacık Bölükbaşı, Aydın Aytekin · 0 citations
Review Open access Sep 2026

Clinicopathological Prognostic Factors After Pulmonary Metastasectomy for Bone and Soft-Tissue Sarcoma: A Single-Centre Retrospective–Prospective Cohort Study

Simple Summary Sarcomas are rare cancers that often spread to the lungs. Surgery to remove the lung metastases is frequently offered, but it is still unclear which patients truly benefit and which are exposed to an operation that will not change the course of their disease. We reviewed 57 patients who underwent 80 lung...

Elisabeth Martínez Téllez, J. Belda Sanchis, Sonia Stephania Chavarría Murillo et al. · 0 citations
Review Open access Sep 2026

Tislelizumab plus chemotherapy followed by anlotinib maintenance therapy in a patient with extensive-stage small cell lung cancer and intracranial recurrence after palliative whole-brain radiotherapy: a case report and literature review

Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancer cases. It is characterized by an exceptionally high proliferative rate, a strong propensity for early metastasis, and a poor prognosis. The median overall survival (OS) following brain metastases development in extensive-stage SCLC (ES-SCLC...

R. Ji, Xia-Lin Chen, Juan Lang et al. · 0 citations
Open access Sep 2026

Prognostic implication of malignant pleural metastases in stage M1a non-small cell lung cancer in a real-world Dutch cohort receiving chemotherapy and/or immunotherapy.

INTRODUCTION In the updated 9th TNM non-small cell lung cancer (NSCLC) staging edition, pleural and pulmonary metastases remain grouped within the M1a category, inferring similar prognostic implications. The aim was to evaluate the prognostic implication on overall survival (OS) of pleural versus contralateral pulmonar...

A. Noordhof, R. A. M. Damhuis, Kevin G. Blyth et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.